Although HRD is not mechanistically linked to MEK or CDK4/6 inhibition yet, we hypothesized that HRD tumors might rely more heavily on compensatory pathways such as MAPK or CDK-mediated cell-cycle checkpoints and thus be indirectly sensitized. The gene discussed is CDK4; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.